182 related articles for article (PubMed ID: 37935098)
1. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Andreadis B; Bartlett NL; Budde LE; Caimi PF; Chang JE; Christian B; DeVos S; Dholaria B; Fayad LE; Habermann TM; Hamid MS; Hernandez-Ilizaliturri F; Hu B; Kaminski MS; Karimi Y; Kelsey CR; King R; Krivacic S; LaCasce AS; Lim M; Messmer M; Narkhede M; Rabinovitch R; Ramakrishnan P; Reid E; Roberts KB; Saeed H; Smith SD; Svoboda J; Swinnen LJ; Tuscano J; Vose JM; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2023 Nov; 21(11):1118-1131. PubMed ID: 37935098
[TBL] [Abstract][Full Text] [Related]
2. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
Zelenetz AD; Gordon LI; Chang JE; Christian B; Abramson JS; Advani RH; Bartlett NL; Budde LE; Caimi PF; De Vos S; Dholaria B; Fakhri B; Fayad LE; Glenn MJ; Habermann TM; Hernandez-Ilizaliturri F; Hsi E; Hu B; Kaminski MS; Kelsey CR; Khan N; Krivacic S; LaCasce AS; Lim M; Narkhede M; Rabinovitch R; Ramakrishnan P; Reid E; Roberts KB; Saeed H; Smith SD; Svoboda J; Swinnen LJ; Tuscano J; Vose JM; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2021 Nov; 19(11):1218-1230. PubMed ID: 34781267
[TBL] [Abstract][Full Text] [Related]
3. SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors.
Nayak RK; Gerber D; Zhang C; Cohen JB
Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):861-865. PubMed ID: 37661513
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
[TBL] [Abstract][Full Text] [Related]
5. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Bartlett NL; Caimi PF; Chang JE; Chavez JC; Christian B; Fayad LE; Glenn MJ; Habermann TM; Lee Harris N; Hernandez-Ilizaliturri F; Kaminski MS; Kelsey CR; Khan N; Krivacic S; LaCasce AS; Mehta A; Nademanee A; Rabinovitch R; Reddy N; Reid E; Roberts KB; Smith SD; Snyder ED; Swinnen LJ; Vose JM; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2019 Jun; 17(6):650-661. PubMed ID: 31200358
[TBL] [Abstract][Full Text] [Related]
6. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
van der Horst HJ; de Jonge AV; Hiemstra IH; Gelderloos AT; Berry DRAI; Hijmering NJ; van Essen HF; de Jong D; Chamuleau MED; Zweegman S; Breij ECW; Roemer MGM; Mutis T
Blood Cancer J; 2021 Feb; 11(2):38. PubMed ID: 33602901
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
[TBL] [Abstract][Full Text] [Related]
8. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
[TBL] [Abstract][Full Text] [Related]
9. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
[TBL] [Abstract][Full Text] [Related]
10. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
Abramson JS; Ghosh N; Smith SM
Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
[TBL] [Abstract][Full Text] [Related]
11. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
12. [CAR-T cells in lymphomas: Current and evolving role].
Messéant O; Houot R
Bull Cancer; 2021 Oct; 108(10S):S28-S39. PubMed ID: 34920805
[TBL] [Abstract][Full Text] [Related]
13. Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents.
Jain N; Mamgain M; Chowdhury SM; Jindal U; Sharma I; Sehgal L; Epperla N
J Hematol Oncol; 2023 Aug; 16(1):99. PubMed ID: 37626420
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib in B-cell Lymphomas.
Maddocks K; Blum KA
Curr Treat Options Oncol; 2014 Jun; 15(2):226-37. PubMed ID: 24481980
[TBL] [Abstract][Full Text] [Related]
15. SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.
Romancik JT; Gerber DG; Zhuang T; Cohen JB
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):557-565. PubMed ID: 35123927
[TBL] [Abstract][Full Text] [Related]
16. Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma.
Mian A; Hill BT
Expert Opin Biol Ther; 2021 Apr; 21(4):435-441. PubMed ID: 33566715
[No Abstract] [Full Text] [Related]
17. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.
Munoz JL; Wang Y; Jain P; Wang M
Curr Oncol Rep; 2022 Oct; 24(10):1299-1311. PubMed ID: 35596920
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.
Ye X; Fan X; Cui R; Mu J; Liu M; Lyu C; Li Y; Chen L; Zhang J; Li X; Wang J; Mou N; Deng Q
Ann Hematol; 2023 Jul; 102(7):1789-1799. PubMed ID: 37171599
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
20. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
Reagan PM; Friedberg JW
Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
